Brind.

Leerink Partners served as the exclusive financial advisor for Heron.

1 report, 1 independent Updated Aug 8

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Heron Leerink partners

Keep exploring

The entities involved

Heron
company in Austria

Nothing else this week.
Leerink partners
U.S. investment bank
- Analyst firm set price targets for Leerink partners' client, Twist Bioscience, on June 26, 2026. Concurrently, the CEO sold shares due to tax withholding obligations.Mon 08:52
- A filing required by the SEC concerning McKesson Corporation shares, accompanied by analyst commentary.Sun 22:38

Related events

Leerink Partners started coverage on ANI Pharmaceuticals shares.Sep 9

Coverage

Newest first; wire copies grouped

Aug 8PR NewswireHeron Therapeutics Announces Comprehensive Capital Restructuring to Support Growth and Extend Maturity Profile CARY, N.C., Aug. 8, 2025 Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Compan